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ABSTRACT 
The prevalence of skin cancer has been continuously increasing in the 
American population over the last 3 decades. Melanoma, the most serious and 
dangerous form, causes the most skin cancer related deaths. If melanoma is 
found early enough, it can be treated and cured. Current therapy for melanoma is 
based on the stage of the disease. It is crucial to identify and treat the melanoma 
before metastasis occurs as the risk of death greatly increases once the disease 
becomes widespread. The processes of angiogenesis and lymphangiogenesis as 
well as changes in the extracellular environment all play significant roles in the 
expansion of a primary melanoma and ultimately metastasis. Neuropilins, 
specifically Neuropilin-2 (NRP2), have been found to be associated with both 
angiogenesis and lymphangiogenesis and thus metastasis. Since it is critical to 
identify and treat melanoma before it advances to metastasis, the relationship 
between NRP2 and tumor progression may prove to be extremely valuable as a 
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prognostic marker for primary melanoma tumors. In addition, it may serve to 
identify subsets of early stage tumors that would benefit from adjuvant therapy. 
This study aimed to demonstrate if there is a relationship between the 
level of expression of NRP2 in primary melanocytic lesions and the prognosis of 
melanoma, and determine the potential utility of NRP2 as a biomarker for 
melanoma. To do so, the levels of expression of NRP2 were analyzed in 
formalin-fixed, paraffin-embedded, tissue samples of nevi, primary melanomas, 
and metastatic melanomas. Sample RNA was extracted and converted to eDNA. 
Quantitative RT -PCR was then used to amplify eDNA and appropriate 
normalizations were performed. Luciferase RNA was added at the start of 
processing as an exogenous control and was used to correct for procedural 
variation between samples. Furthermore, Actin, beta (ACTB) and Melan-A were 
used as reference genes to correct for differences in tissue and lesion size 
respectively. To analyze the data, standard curves were developed for NRP2, 
ACTB, and Melan-A to calculate the copy numbers for each gene in each 
sample. 
When normalized by both ACTB and Melan-A, the differences in the level 
of expression of NRP2 between nevi and primary melanomas (p=0.94422), nevi 
and metastatic melanomas (p=0.29538), and primary melanomas and metastatic 
melanomas (p=0.32827) all failed to show statistical significance. In addition 
when normalized by only ACTB, there is no statistical significant difference in the 
level of expressio11 of NRP2 between nevi and primary melanomas (p=0.21001 ), 
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or primary and metastatic melanomas (p=0.30874). However, there is a 
difference between nevi and metastatic melanomas (p=0.004 72) that is 
statistically significant when just normalized by ACTB. Furthermore, when just 
normalized by Melan-A, there is no significant difference in the level of 
expression of NRP2 between nevi and primary melanomas (p=0.3152) or primary 
melanomas and metastatic melanomas (p=0.14179). However, there is a 
statistically significant difference in the level of expression of NRP2 between nevi 
and metastatic melanomas (p=0.01736). The fact that there is a statistically 
significant difference (p<0.05) in the level of expression of NRP2 between nevi 
and primary melanomas demonstrates its potential ability to be used as a 
biomarker. However, the inability to establish statistical significance between 
sample groups may be due to the small sample size. Further studies with an 
increased sample size may better show the relationship between the levels of 
NRP2 and the stage of melanoma. Still, NRP2 shows promise as both a 
diagnostic and prognostic biomarker for melanoma. 
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INTRODUCTION 
Skin Cancer 
The prevalence of skin cancer has been continuously increasing in the 
American population over the last 3 decades and is currently the most common 
type of cancer in the United States with over 2 million cases diagnosed annually. 
Melanoma, the mqst serious and dangerous form, causes the most skin cancer 
related deaths (American Cancer Society, 2012). The American Cancer Society 
approximates that each year there are 75,000 new cases of invasive melanoma 
diagnosed and that the disease kills over 8,000 people annually in the United 
States. 
If found early enough melanoma can be treated and cured. As you get 
older, the risk of acquiring melanoma increases; still the disease can be detected 
in patients of any age (Miller and Mihm, 2006). A family history of melanoma, fair 
skin, the presence of multiple atypical nevi, and immunosuppression are all risk 
factors that increase a person's chance of developing melanoma. The cancer 
can occur anywhere on the skin, from the neck and face to the eyes and mouth 
(American Cancer Society, 2012). The most common site that melanoma is 
found in men is tlw trunk and in women is the legs. 
Melanoma originates from particular cells in the skin called melanocytes. 
The skin has thre~ 1ayers: the epidermis, the dermis and the hypodermis. The 
epidermis is the outermost layer while the hypodermis is the innermost. The 
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epidermis is mainly comprised of keratinocytes. There are no blood vessels or 
lymphatics in the epidermis. The layer is nourished via diffusion from blood 
vessels located in the dermis and hypodermis. Melanocytes are found in the 
dermal-epidermal junction of the skin as well as in hair follicles (Hearing and 
Leong, 2006). They produce a substance known as melanin, which gives rise to 
skin and hair color. An external stimulus, such as ultraviolet light, can cause 
melanocytes to increase melanin production, which serves as a protective 
mechanism for the skin (Hearing and Leong, 2006, Merk, 2011 ). Unfortunately, if 
the stimulus causes DNA damage, the melanocyte may become abnormal and 
start to reproduce uncontrollably leading to melanoma (Merk, 2011 ). When these 
cancerous cells spread to other parts of the body such as the brain, lungs, liver, 
or bone, metastasis occurs. However, this is not a simple process. The cell 
needs to separate from the primary site, migrate into a blood or lymphatic vessel, 
survive as it travel15 through and exits the blood or lymphatic vessel, and then be 
able to replicate at the secondary site (Stine et al., 2011 ). It is crucial to identify 
and treat the melanoma before metastasis occurs as the risk of death greatly 
increases once the disease becomes widespread. 
Once the melanoma becomes metastatic, it becomes extremely difficult to 
treat. This is because of the molecular heterogeneity of the tumor and the ability 
to resist apoptotic processes as well as chemotherapeutics (Soengas and Lowe, 
2003). This is why it is critical to detect the disease as early as possible. 
Typically, a biopsy will be taken of the initial lesion and will be checked for 
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cancerous cells via histological examination (Garb et al., 201 0). Once it is 
identified as melanoma, other factors are assessed such as thickness, 
ulcerations, microsatellites, and how far the cancer has spread. 
Melanoma Staging 
Melanoma diagnosis is done via staging based on the American Joint 
Committee on Cancer (AJCC) system. Staging the melanoma involves physical 
exams, imaging and laboratory tests, as well as pathology and surgical reports 
(National Cancer Institute, 2011 ). Stages range from 0-IV. Stage 0, melanoma in 
situ, refers to the presence of abnormal melanocytes in the epidermis. Stage I is 
subdivided into lA and lB. In stage lA, the lesion is <1 mm thick with no 
ulcerations and a mitotic rate <1/HPF whereas in stage IB the lesion is either 
<1mm thick and shows ulcerations, possesses a mitotic rate ~ 1/HPF, or is 
between 1 mm and 2mm thick with no ulcerations. There are three sub-stages for 
stage II. In stage I lAthe thickness is between 1 and 2 mm with ulcerations or 
between 2 and 4mm with no ulcerations. In stage liB, the tumor is between 2 and 
4 mm thick with ulcerations or more than 2mm thick with no ulcerations. Stage 
lie refers to the tumor being more than 4mm thick and having ulcerations. In 
stage Ill, the thickness of the tumor varies and it may or may not have 
ulcerations. However, the cancer has begun to spread to other areas under the 
skin not more than 2 em away, the lymph vessel between the primary site and 
the lymph nodes, or the actually lymph nodes (National Cancer Institute, 2011 ). 
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Stage IV is the most advanced stage of metastatic disease and is identified as 
the stage in which melanoma has metastasized to secondary organs in the body 
or distant lymph nodes. A summary of the stages is shown in Table 1. 
The Sta es of Melanoma 
Table 1. Summary of the characteristics of each stage of Melanoma. 
Table taken from Moncrieff, 2011 at 
http://skincancersurgery .co.uk/Melanoma/Melanoma _staging .html 
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Melanoma Treatment 
Current therapy for melanoma is based on the stage of the disease. The 
standard treatment is surgery to remove the lesion (Garbe et al., 2011 ). If the 
tumor has spread to the lymph nodes, a lymphadenectomy is advised (Garbe et 
al, 2010). In addition to surgery, patients with stage II and Ill melanoma may 
undergo chemoth~rapy and/or radiation therapy, and are possibly placed in 
.c1inical trials (Garbe et al, 2011 ). lnferfeuron-a is sometimes used as an 
adjuvant therapy and has shown a modest increase in survival in some studies. 
Combination chemotherapy proves to be more promising than single-agent 
chemotherapy however there is a greater risk for toxicity (Bhatia et al., 2009). 
Dacarbazine and high does IL-2 are chemotherapeutic agents approved in the 
United States for metastatic melanoma treatment. However, there is no 
significant increase in survival for these agents. 
The scientific community continues to find improved targeted therapies for 
advanced staged melanoma. In particular, BRAF inhibitors, such as vemurafenib, 
have shown promise in regards to treatment for melanoma with BRAF mutations 
(Livingstone et al., 2012). BRAF is an intermediary kinase in the mitogen-
activated protein kinase (MAPK) signaling pathway that regulates cell 
proliferation. Mutations in BRAF promote activation of the pathway and thus 
increase cell proliferation. Inhibitors that target BRAF mutations can prevent the 
lesion from increa$ing in size. Studies have demonstrated that vemurafenib has 
increased the length of survival of melanoma patients, however resistance to the 
5 
drug and long-term term survival need to be further examined, seeing that 
patients have quickly developed resistance to the BRAF inhibitor (Flaherty et al., 
201 0). Other kinase inhibitors of signaling pathways such as MEK inhibitors, and 
c-KIT inhibitors are also being studied for target therapy (Livingstone et al., 
2012). In addition to these pathway inhibitors, lpilimumab is a monoclonal 
antibody that has shown to improve overall survival for patients with metastatic 
melanoma. lpilimumab acts by blocking cytotoxic T -lymphocyte-associated 
antigen 4 (CTLA-4) (Robert and Ghiringhelli, 2009). CTLA-4 is a negative T-cell 
regulator and blocking this would allow for increased T -cell mediated tumor 
response. However, autoimmune adverse effects are associated with ipilimumab 
treatment. Still, ipilimumab displays promise as a targeted therapy for advanced 
staged melanoma, 
Several models of melanoma progression have been proposed in the 
scientific community. The theory that metastatic melanoma is derived from pre-
existing benign nevi was initially suggested by Virchow (Ferreira de Souza et al., 
2012). Clark further hypothesized that melanocytes proliferate and transform into 
nevi and acquire dysplasia, hyperplasia, invasion, and finally metastasis (Miller 
and Mihm 2006). A Nevus is characterized as a benign lesion that contains 
melanocytes. Nevi, however, do not typically progress to be melanoma because 
they have restricted growth. In order for melanoma to develop, there needs to be 
mutations on a genetic level that leads to an increase in growth as well as 
diminished DNA repair and cell death (Miller and Mihm, 2006). With these 
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genetic mutations, the cells have the ability to further multiply without being 
turned off. Eventually the lesion not only grows laterally, but also grows vertically, 
deeper into the skin where the cells can come in contact with lymphatics or blood 
vessels. Here, alterations in cell motility, cell extension, and cell adhesion can 
allow the malignant cells to metastasize and form secondary tumors in other 
parts of the body (Ferreira de Souza et al., 2012). Another theory of melanoma 
progression involves tumor stem cells with the ability of self-renewal, and a high 
tumorogenicity (Zabierowski and Herlyn, 2008). Metastasis is aided by the 
microenvironment that contains fibroblasts, endothelial cells, and inflammatory 
cells (Ferreira de Souza et al., 2012). Other models hypothesize that melanoma 
progression is a result of epigenetic changes, such as DNA methylation, within 
tissue specific stem cells (Feinberg et al., 2006). This malignant transformation is 
caused by tumor suppressor gene inactivation and oncogene activation, which 
allows the cells to multiply uncontrollably. It is likely that all of these processes 
are involved in the development and progression of melanoma to a varying 
degree in individual lesions. 
Angiogenesis and Melanoma 
The process of angiogenesis plays a significant role in the expansion of a 
primary melanoma and ultimately metastasis (Mahabeleshwar and Byzova, 
2007). As the tumor progresses and grows, it requires oxygen and nutrients that 
cannot simply diffuse through the initial surrounding environment due to 
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increased tumor volume. Thus, the malignant lesion secretes growth factors that 
ultimately allow for an increase in vascular channels to the tumor, a process 
known as tumor-associated angiogenesis (Ria et al., 201 0). In particular, the 
advancement from lateral growth to vertical growth is associated with the 
secretion of vascular endothelial growth factor (VEGF) by melanoma cells 
(Erhard et al., 1997). Other stimulators for angiogenesis in melanoma include 
fibroblast growth factor-2 (FGF-2), as well as the placental growth factor (PGF) 
(Ordorisio et al., 2006, Ribatti et al., 2003). Tumor cell secretion of matrix 
metalloproteinases (MMPs) leads to breakdown of the extracellular matrix 
leading to subseq1.,1ent release of the angiogenic growth factor, FGF-2. 
Melanoma cells express PGF, which is a member of the VEGF family that binds 
neuropilin-1 (NRP1) and neuropilin-2 (NRP2) leading to enhanced tumor-
associated angiogenesis (Ordorisio et al., 2006). 
Another key component in tumor metastasis is the interaction of the tumor 
with its surrounding environment, particularly endothelial cells (Stine et al., 2011 ). 
Again, for the melanoma to metastasize, cancer cells must migrate towards, 
adhere to, and enter the blood or lymphatic system. For this to occur, molecular 
pathways pertaining to cell adhesion, cell differentiation, cell migration, and 
extracellular matrix remodeling are upregulated (Stine et al., 2011 ). In addition to 
changes in cell communication and angiogenesis, lymphangiogenesis plays a 
role in melanoma metastasis (Rushing et al., 2011 ). The interaction between the 
cancer cells and the endothelium of the lymphatic and vascular vessels is thus 
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critical for tumor expansion. VEGF modulates the restructuring and proliferation 
of endothelial cells with the help of neuropilins. Therefore, neuropilins are 
believed to play a key role in metastasis. 
Neuropil ins 
Neuropilins are upregulated in several tumor types and their expression is 
shown to correlata with tumor development (Staton et al., 2007). There are 
currently two known neuropilins: neuropilin-1 (NRP1 ), and neuropilin-2 (NRP2). 
They are both transmembrane glycoproteins with large extracellular domains and 
a cytoplasmic domain that lacks enzymatic activity (Favier et al., 2005, Staton et 
al, 2007). The extracellular domain has subdomains including an a1a2 domain 
that binds class-3 semaphorins, a b1b2 domain that binds VEGF, and a c domain 
that is involved in dimerization (Mamluk, 2002). The basic structure of neuropilins 
can be viewed in Figure 1. 
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Figure 1. A depiction of the neuropilin structure and its domains as well as 
its association with common receptors. Figure taken from Staton et al , 
2007. 
Neuropilins were first discovered to be co-receptors for class-3 
semaphorins and were found to be involved in axonal growth guidance during 
embryologic development (Cai and Reed, 1999). Subsequently, neuropilins were 
found to serve as co-receptors for VEGF and contribute to angiogenesis (Mamluk 
et al., 2002). It is notable that neuropilins have been found to be present in 
multiple tissue types (Bielenberg et al., 2006). NRP1 and NRP2 have similar 
structures but differ in their expression throughout the body as well as in their 
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regulation and binding properties. For example, in embryonic endothelium, NRP1 
is expressed in arterial endothelium while NRP2 is expressed in venous and 
lymphatic endothelium. Studies show that knocking out NRP1 is lethal in mice 
while knocking out NRP2 diminishes lymphatics and capillaries (Bielenberg et al., 
2006, Ellis, 2006). 
Both neuropilins are associated with tumor cells; however, the expression 
of each neuropilin varies depending on the type of cancer. For example, NRP1 is 
seen in epithelial c:;arcinomas like prostate, colorectal, lung, and breast cancers 
whereas melanoma cells, human glioblastoma cells, and human neuroblastoma 
cells all express NRP2 suggesting that expression of NRP2 is restricted to 
tumors derived from the neural crest (Bielenberg et al., 2006, Ellis, 2006). In 
addition, the expression of neuropilins may be associated with the progression of 
a particular tumor and correlate with a worse prognosis. For example, NRP2 
expression is associated with more advanced stages of bladder cancer (Ellis, 
2006). 
Since it is critical to identify and treat melanoma before it advances to 
metastasis, the relationship between NRP2 and tumor progression may prove to 
be extremely valuable as a prognostic marker for primary tumors and may serve 
to identify subsets of early stage tumors that would benefit from adjuvant therapy. 
Currently, the mm~t useful tumor characteristics for predicting the prognosis of 
primary melanomas are the phenotypic aspects of the disease such as the 
thickness of the lesion, proliferative index, and whether there is ulceration seen in 
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the primary lesion. Whether a particular primary melanoma lesion will remain 
limited to skin or metastasize to distant sites remains extremely difficult to 
determine at the time of biopsy. A reliable biomarker, such as NRP2, may 
provide insight as to whether metastasis is predicted to occur in a particular 
lesion and whether adjuvant therapies might be considered for a particular tumor. 
Melanoma Biomarkers 
The National Cancer Institute defines a biomarker as a biological molecule 
found in blood, body fluids, or tissues that is a sign of a normal or abnormal 
process, a condition, or a disease (National Cancer Institute, 2011 ). A melanoma 
biomarker would not only be an efficient way of diagnosing the disease, but also 
aid in prognosis and further show how the tumor is responding to treatment. The 
National Cancer Institute's Surveillance, Epidemiology, and End Results Program 
(SEER) Cancer Statistics Review states that from 2001 to 2007, the 5-year 
relative survival at the time of diagnosis for localized lesions that remain at the 
primary site was 98.2%, for regional tumors that spread to the lymph nodes was 
61.7%, and for distant melanomas that have metastasized was 15.2% 
(Howlander et al., 201 0). A melanoma biomarker could substantially increase 
survival rates among patients with early stage melanoma either to improve 
diagnosis of primary malignant lesions or predict the outcome for localized 
disease and whether such disease would warrant additional therapies. In addition 
to increased survival, being able to screen for the biomarker and then provide a 
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targeted therapy specific to the biomarker would allow for a more cost effective 
approach for identifying and treating melanoma (Atherly and Camidge, 2012). 
The scientific community has identified several melanoma biomarkers. 
Some only state the presence of melanocytic/melanoma cells such as MART-
1/Melan-A, Tyosinase, Mitt, and gp100 (Medic et al., 2006). Other proposed 
biomarkers have a connection with the progression of melanoma such as 
Nuclear Factor Kappa B (NFkB), which is associated with the transition from 
radial growth to vertical growth and from pro-apoptotic to anti-apoptotic. In 
addition, factors that are associated with angiogenesis such as VEGF-C and 
VEGF-0 as well as those associated with lymphangiogenesis such as lymphatic 
endothelial hyaluronal receptor-1 (L YVE-1) aid in the analysis of the tumor 
(Medic et al., 2006). 
Objectives 
NRP2 has emerged as a promising biomarker because it is associated 
with angiogenesis and lymphangiogenesis in melanoma. NRP2 may show 
utilization when differentiating between primary melanomas of low metastatic 
potential and primary melanomas of high metastatic potential. The goals of the 
current study is to demonstrate if there is a relationship between the level of 
expression of NRP2 in primary melanocytic lesions and the prognosis of 
melanoma, and determine the potential utility of NRP2 as a biomarker for 
melanoma. 
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METHODS 
Sample Selection 
Patient samples were randomly selected and provided by the Department 
of Dermatology at Boston University School of Medicine, Boston, MA. Samples 
were in the form of formalin-fixed, paraffin-embedded tissues and consisted of 
nevi (n = 12), primary melanomas (n = 11 ), and metastatic melanomas (n = 12) in 
order to assess the level of expression of NRP2 throughout different phases of 
the disease. Two to four tissue slides were used from each patient sample for 
processing and analysis. All of the primary melanomas had a depth equal to or 
less than 1.65 mm. Four of these primary melanomas possessed ulcerations; 
however, none experienced vascular invasion or microsatellites. 
RNA Extraction and Isolation 
Tissue samples were processed with Arcturus Paradise PLUS Whole 
Transcript Reverse Transcription Reagent System from Applied Biosystems by 
Life Technologies. RNA extraction and isolation was performed according to 
manufacturer's im~tructions. In summary, tissue slides underwent a series of 
Xylene washes for a total of 15 minutes to remove the paraffin. The tissue 
samples were then scraped and incubated with a Proteinase K solution for 16 to 
20 hours. Following the incubation, 1 Ong of luciferase RNA was added to each 
sample as an internal control for processing and analysis. Sample RNA was 
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isolated using a conditioned purification column along with a binding buffer and 
ethanol solution. The samples then underwent a series of washes and finally an 
elution buffer was used to isolate approximately 11~L of RNA. DNase treatment 
was also performed according to manufacturer's instructions to ensure the RNA 
sample was clean and free of contaminating DNA. 
Reverse Transcription 
The isolated RNA was converted to eDNA using SuperScript Ill First-
Strand Synthesis System for RT-PCR by Invitrogen. Reverse transcription was 
carried out according to manufacturer's instructions. One third, about 4.5f!L of 
each isolated RNA was used for eDNA synthesis. The RNA was primed with 
random hexamers, combined with 1 OmM dNTP mix, and denatured at 65"C for 5 
minutes then 4 ·c for at least 1 minute. A previously prepared eDNA synthesis 
mix containing 1 OX RT Buffer, 25mM MgCI2, 0.1 M OTT, RNaseOUT, and 
SuperScript Ill RT was then added and the samples were heated to 25"C for 10 
minutes, SO"C for 50 minutes, and a·c for 5 minutes. RNase H was then added 
and the samples were heated to 3TC for 20 minutes. The entire procedure 
yielded approximately 20~-tl of eDNA for each sample. 
Primer Design 
Primers for qRT-PCR were designed for the genes NRP2, Actin, beta 
(ACTB), Melan-A, and Luciferase, using the program Primer Blast provided by 
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the PubMed website and then ordered through Invitrogen. Each nucleotide was 
searched for the Homo sapiens sequence and selected primers were between 80 
and 100 base pairs. Once received, the primers underwent optimization and 
appropriate annealing temperatures were determined. The primer sequence for 
each gene is shown in Table 2: 
Primer Sequences 
NRP2 
Forward: 5'-GAGTACCAGA TTGTGTTC-3' 
Reverse: 5'-CTTATCCGAATGTCATCAA-3' 
ACTB 
Forward: 5' -GCATTGTTACAGGAAGTCC-3' 
Reverse: 5' -CA TT ACAT AA TTTACACGAAGC-3' 
Me/an-A 
Forward: 5'-AGGAAGGTGTCCTGTGCCCTGA-3' 
Reverse: 5' -GAGTGGCCGTGCCCCTICTTG-3' 
Luciferase 
Forward: 5'-TCAGGTGGCCCCCGCTGAAT-3' 
Reverse: 5' -GTCGGGAAGACCTGCCACGC-3' 
Table 2. Forward and reverse nucleotide sequences for primers used to 
amplify sample eDNA in qRT -PCR. Size ranged from 80 to 1 00 base 
pairs. 
qRT-PCR 
MyiQ Single-Color Real-Time PCR Detection System by Bio-Rad was 
used to amplify eDNA samples for analysis. Protocol was designed based on 
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manufacturer's recommendations. All samples were run at once in duplicates 
with both positive !3nd negative controls, using only one primer per run to 
minimize bias, for a total of four runs. The positive control was eDNA derived 
from melanoma cell line WM35 and the two negative controls consisted of a 
mock from the eDNA synthesis and a mock of only nuclease free distilled water. 
A 96-well plate was used in each procedure and each well contained O.Sf..ll 
eDNA, 12.5!-ll Sybr Green Master Mix provided by Bio-Rad, 0.25!-ll of the 
forward primer, 0.25!-ll of the reverse primer, and 11.5!-ll of nuclease free 
distilled water. All samples were heated to 95"C for 5 minutes then ran for 60 
cycles of 95"C for 0.5 minutes, SS"C for 0.5 minutes, and 72"C for 0.5 minutes, 
and then finally heated to 95"C for 1 minute and 65"C for 1 minute. The MyiQ 
software provided with the detection system determined the cycle threshold (Ct) 
values for the samples and generated melting curves to make sure the correct 
fragment was amplified. However, the Ct baseline for all samples was manually 
set at 50 to ensure standardization throughout each run for each primer. 
Standard Curves 
For sample analysis, standard curves for each gene were generated to 
determine gene copy numbers in each tissue sample. First, qRT -PCR was 
performed to ampljfy eDNA from melanoma cell line WM35 with 500 base pair 
primers for the genes NRP2, ACTB, and Melan-A. The 500 bp primers were 
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designed using the same Primer Blast tool as the short primers. The sequences 
are shown in Table 3. 
Primer Sequences 
NRP2 
Forward: 5' -CGGCTTTTGCAGTGGACATCCCA-3' 
Reverse: 5' -CCCTGTGCGGCTGCATCTCC-3' 
ACTB 
Forward: 5' -CACAGAGCCTCGCCTTIGCCG-3' 
Reverse: 5' -ACGGCCAGAGGCGTACAGGG-3' 
Me/an-A 
Forward: 5'-TGCAGAACAGTCACCACCACCT -3' 
Reverse: 5' -GGCCAGTCAACCCTTTGTCTTAACC-3' 
Table 3. Forward and reverse nucleotide sequences for 500 base pair 
primers used to amplify DNA in qRT-PCR. 
Gel electrophoresis was then run with the amplified qRT -PCR samples in 2% 
agarose gel. The band was excised and DNA was extracted using Qiagen QIA 
Quick Gel Extraction Kit. The DNA concentration was determined with Bio-Rad 
Smart-Spec Plus Spectrometer and 1 0 fold dilutions were made starting with 
1ng. The dilutions were then run in duplicate forqRT-PCR with the 500 bp 
primers and Ct values were determined. The copy numbers were generated from 
the following formt,Jia: m = [n][1.096e-21 g/bp], where n = 500 and m = mass of 
one gene copy. A ratio was then set up to determine how many copies were in 
each dilution. The copy numbers were then plotted against Ct values and the 
equation of the linear slope was used in analysis of tissue samples. 
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RESULTS 
To evaluate the possible utility of NRP2 as a biomarker for melanoma, the 
level of expression of NRP2 was assessed in formalin-fixed, paraffin-embedded 
tissues of nevi, primary melanomas, and metastatic melanomas. Quantitative 
RT-PCR was performed and sample eDNA was amplified with NRP2, ACTB, 
Melan-A, and Luciferase primers. To minimize statistical error from procedural 
variation between samples, 1 Ong Luciferase RNA was added as an exogenous 
control to each sample RNA before processing. The Ct values obtained from 
amplification with Luciferase primers were then used to normalize the Ct values 
obtained from amplification with NRP2, ACTB, and Melan-A primers, allowing for 
a more accurate statistical analysis. Once this normalization was performed, the 
copy numbers of NRP2, ACTB, and Melan-A were determined using the 
equations obtained from the standard curves. The standard curves for NRP2, 
ACTB, and Melan.,.A are shown in Figures 2a, 2b, and 2c respectively, along with 
the corresponding equation to calculate gene copy numbers. 
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Figure 2a. The cycle threshold (Ct) value (x) of each NRP2 dilution was 
plotted against the corresponding copy number (y). As the NRP2 DNA 
solution becomes more diluted, the Ct value increases and the number of 
NRP2 gene copies decreases. 
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Figure 2b. The cycle threshold (Ct) value (x) of each ACTB dilution was 
plotted against the corresponding copy number (y). As the ACTB DNA 
solution becomes more diluted, the Ct value increases and the number of 
ACTB gene copies decreases. 
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Figure 2c. The cycle threshold (Ct) value (x) of each Melan-A dilution was 
plotted against the corresponding copy number (y). As the Melan-A DNA 
solution becomes more diluted, the Ct value increases and the number of 
Melan-A gene copies decreases. 
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The copy numbers for NRP2, ACTB, and Melan-A can be seen in 
Tables 4a, 4b, and 4c respectively. 
Copy Number of NRP2 in Each Sample 
Primary Metastatic 
Nevi 
Melanomas Melanomas (n=11) (n =11) (n = 12) 
24498.65 85184.29 7270.40 
31047.35 35926.72 1463534.66 
22018.00 2244.32 9980.16 
28177.76 113623.17 87667.21 
22946.47 28729.20 51-887.08 
21573.15 24188.65 5503117.84 
10538.80 23609.43 220911.56 
22841.52 358.97 131480.94 
9512.18 3322.77 28964.14 
45609.44 2938708.64 474692.14 
341810.29 19860.88 659355.96 
64385.22 
Table 4a. NRP2 copy numbers were calculated using the equation 
y = 2E+1Z0·53x, where x =cycle threshold value andy= number of NRP2 
gene copies in the sample. The equation was obtained from the 
corresponding standard curve seen in figure 1 a. n = sample size of each 
group. The mean copy number of NRP2 in nevi was 52, 779.42, in primary 
melanomas was 289,159.7, and in metastatic melanomas was 
725,270.61. Any sample that did not amplify in qRT-PCR or showed a 
poor melting curve was negated. 
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Copy Number of ACTB in Each Sample 
Primary Metastatic 
Nevi 
Melanomas Melanomas (n = 12) (n =11) (n = 12) 
262821.37 749462.66 36150.78 
798751.97 409322.75 1540994.64 
279819.32 34516.19 9601 .35 
327142.58 267363.99 92305.02 
69651 .71 -44166.29 88180A9 
445615.19 16644.40 25120972.46 
38968.88 63572.18 579622.05 
440912.44 72334.08 818224.23 
206628.38 56062.61 300142.39 
5372.22 16943299.22 1051441 .51 
474047.35 143928.22 2450935.17 
2106183.04 344534.03 
Table 4b. ACTB copy numbers were calculated using the equation 
y = 1 E+1Z0·50x, where x =cycle threshold value andy= number of ACTB 
gene copies in the sample. The equation was obtained from the 
corresponding standard curve seen in figure 1 b. n = sample size of each 
group. The mean copy number of ACTB in nevi was 454,659.54, in 
primary melanomas was 1, 709,152.06, and in metastatic melanomas was 
2,702,758.68. Any sample that did not amplify in qRT-PCR or showed a 
poor melting curve was negated. 
24 
Copy Number of Melan-A in Each Sample 
Primary Metastatic 
Nevi 
Melanomas Melanomas (n = 12) (n =11) (n = 12) 
1686.57 2593.12 329.00 
7517.80 581.30 10242.34 
3969.10 173.73 108.83 
1194.74 94.87 1460.63 
181 .61 -0 . .02 230 . .89 
3431.33 77.25 173933.67 
203.19 448.92 784.99 
11678.39 68.13 698.75 
866.92 191.27 325.30 
197.14 t59864.31 14440.67 
6385.64 1265.58 36302.30 
57030.36 7446.72 
Table 4c. Melan-A copy numbers were calculated using the equation 
y = 7E+1 r 0·63x , where x = cycle threshold value and y = number of Melan-
A gene copies in the sample. The equation was obtained from the 
corresponding standard curve seen in figure 1 c. n = sample size of each 
group .. The mean copy number of Melan-A in nevi was 7,861.90, in 
primary melanomas was 15,032.59, and in metastatic melanomas was 
20,525.34. Any sample that did not amplify in qRT-PCR or showed a poor 
melting curve was negated. 
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Once the copy numbers for each gene were computed, further 
normalizations were performed to provide more reliable results. ACTB is found 
throughout skin cells and was used as a reference gene in qRT-PCR to correct 
for the size of the entire tissue sample. Mel an-A is found in melanocytes and was 
used as a reference gene to correct for the size of just the lesion. Furthermore, 
any sample that did not amplify in qRT -PCR or showed an incorrect melting 
curve was negated from the analysis. 
When normalized by only Luciferase, the mean level of expression of 
NRP2 in nevi was 52,779.42 copies, in primary melanomas was 289,159.73 
copies, and in metastatic melanomas was 725,270.61 copies. Then, when 
normalized by ACTB, the mean level of expression of NRP2 in nevi was 635.65 
copies, in primary melanomas was 1 ,556.43 copies, and in metastatic 
melanomas was 2,459.23 copies. The relative levels of expression of NRP2 
when normalized by Luciferase and ACTB are depicted in figures 3a and 3b. 
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Figure 3a. A bar graph depicts the copy numbers of NRP2 when 
normalized by ACTS among nevi, primary melanomas, and metastatic 
melanomas. The numbers next to each group correspond to the sample 
size. Any sample that did not amplify in qRT -PCR or showed a poor 
melting curve was negated. 
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Figure 3b. A box and whisker plot showing the p-values and relative 
expression of NRP2 among nevi (n=11 ), primary melanomas (n=11 ), and 
metastic melanomas (n=12) when normalized by ACTB. Arrows 
correspond to the calculated p-value between those two groups. P-values 
were caluclated using two-tailed hypothesis testing assuming equal 
variances. Any sample that did not amplify in qRT -PCR or showed a poor 
melting curve was negated. 
When just normalized by Luciferase and Melan-A the mean level of 
expression of NRP2 in nevi was 4630.28 copies, in primary melanomas was 
9,050.67 copies, and in metastatic melanomas was 19,572.76 copies. The 
relative levels of expression of NRP2 when normalized by Luciferase and Melan-
A are depicted in Figures 4a and 4b. 
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Figure 4a. A bar graph depicts the copy numbers of NRP2 when 
normalized by Melan-A among nevi, primary melanomas, and metastatic 
melanomas. The numbers next to each group correspond to the sample 
size. Any sample that did not amplify in qRT-PCR or showed a poor 
melting curve was negated. 
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Figure 4b. A box and whisker plot showing the p-values and relative 
expression of NRP2 among nevi (n=11 ), primary melanomas (n=9), and 
metastic melanomas (n=12) when normalized by Melan-A. Arrows 
correspond to the calculated p-value between those two groups. P-values 
were caluclated using two-tailed hypothesis testing assuming equal 
variances Any sample that did not amplify in qRT -PCR or showed a poor 
melting curve was negated. 
Finally the NRP2 copy numbers were normalized by both ACTB and 
Melan-A. Using all three genes for normalization of data, the mean level of 
expression of NRP2 in nevi was 326.10, in primary melanomas was 308.71, and 
in metastatic melanomas was 1282.51. The relative levels of expression of NRP2 
when normalized by luciferase, ACTB, and Melan-A are depicted in Figures 5a 
and 5b. 
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Relative Level of Expression of NRP2 when 
normalized by ACTB and Melan·A 
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Figure Sa. A bar graph depicts the copy numbers of NRP2 when 
normalized by ACTB and Melan-A among nevi, primary melanomas. and 
metastatic melanomas. The numbers next to each group correspond to 
the sample size. Any sample that did not amplify in qRT -PCR or showed a 
poor melting curve was negated. 
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Figure 5b. A box and whisker plot showing the p-values and relative 
expression of NRP2 among nevi (n=11 ), primary melanomas (n=9), and 
metastic melanomas (n=12) when normalized by ACTB and Melan-A. 
Arrows correspond to the calculated p-value between those two groups. 
P-values were caluclated using two-tailed hypothesis testing assuming 
equal variances. Any sample that did not amplify in qRT-PCR or showed a 
poor melting curve was negated. 
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DISCUSSION 
It is observed that there are varying levels of expression of NRP2 among 
nevi, primary melanomas, and metastatic melanomas, thus demonstrating that 
NRP2 shows promise as a biomarker for melanoma. To further assess the 
relationship between the level of expression of NRP2 in primary melanocytic 
lesions and the prognosis of melanoma, p-value analysis was performed. P-
values were calculated using two-tailed hypothesis testing and assuming equal 
variances between nevi and primary melanomas, nevi and metastatic 
melanomas, and primary melanomas and metastatic melanomas among all of 
the performed normalizations. 
In theory, using both ACTB and Metan-A to correct for differences 
between tissue samples should provide the most statistically accurate analysis. 
Unfortunately for this normalization, the differences in the level of expression of 
NRP2 between nevi and primary melanomas (p=0.94422), nevi and metastatic 
melanomas (p=0.29538), and primary melanomas and metastatic melanomas 
(p=0.32827) all failed to show statistical significance. In addition when 
normalized by only ACTB, there is no statistical significant difference in the level 
of expression of NRP2 between nevi and primary melanomas (p=0.21 001 ), or 
primary and metatastic melanomas (p=0.3087 4 ). However, there is a difference 
between nevi and metastatic melanomas (p=0.00472) that is statistically 
significant when just normalized by ACTB. Furthermore, when just normalized by 
Metan-A, there is no significant difference in the level of expression of NRP2 
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between nevi and primary melanomas (p=0.3152) or primary melanomas and 
metastatic melanomas (p=0.14179). However, there is a statistically significant 
difference in the level of expression of NRP2 between nevi and metastatic 
melanomas (p=O.Q1736). 
The fact that there is a statistically significant difference in the level of 
expression of NRP2 between nevi and primary melanomas demonstrates its 
ability to be used as a biomarker. Again, NRP2 is a protein expressed during 
angiogenesis and ·lymphangiogensis. In order for metastasis to occur and for the 
tumor to be able to spread to other parts of the body, these processes are 
crucial. Thus it is logical that the levels of NRP2 would continue to increase as 
both angiogenesis and lymphangiogenesis become more and more evident, or 
as the cancer progresses to become metastatic. Since both nevi and primary 
melanomas show no sign of metastasis it is acceptable that their levels of 
expression of NRP2 are not significantly different. A reason as to why there is no 
significant difference in the level of expression between primary melanomas and 
metastatic melanomas may be because even though the primary tumor has no 
signs of vascular or lymph invasion, there still may be something developing in 
the lesion to prepare for such processes. This is where establishment of a 
threshold for the level of expression of NRP2 may serve as prognosis factor for 
melanoma. It wol,JJd be able to determine primary melanomas of low metastatic 
potential versus primary melanomas of high metastatic potential. For instance, if 
this sort of analysis was performed on a tissue biopsy, one could use this 
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threshold to determine if the lesion is going to progress to be metastatic and 
therefore give the patient a more accurate report on the current and future state 
of the disease. 
Small sample size may also be a contributing factor as to why there is no 
difference among selected groups. The inadequate sample size may lead to 
invalid inferences pecause it has a decreased probability of providing a result 
that is statistically significant (Kalla, 2009). Unfortunately, resources were limited 
and the experiments could only be performed on the formalin-fixed paraffin-
embedded tissue sections that were available. Assessing the NRP2 expression 
level in a larger sample size may be the next step in this study. Increasing the 
size would offer a more accurate result and thus a more legitimate conclusion. 
In addition to increasing sample size, one may consider analyzing other 
potential biomarkers in order to develop somewhat of a multi-biomarker panel for 
evaluating melanoma. This is because tumor-related gene expression tends to 
be heterogeneous in melanoma (Medic et al., 2006). The levels of expression 
vary among lesions as seen in the NRP2 data from this experiment. Having more 
than one biomarker to analyze in the cancer would improve the methods for both 
diagnosis and prognosis and give the patient a more accurate assessment of 
their condition. In addition one could test the levels of expression to determine 
the effects of treatment on the patient. 
In conclusion, the results from this study show that there is a potential 
relationship between the levels of expression of NRP2 and the different stages of 
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melanoma. In particular there is a statistically significant difference (p<0.05) in 
the level of NRP2 expression between the nevi tissues that were analyzed and 
the metastatic melanoma tissues that were analyzed, inferring that NRP2 does 
play a role in metastasis and could be used as both a diagnostic and prognostic 
biomarker for melanoma. Due to the limitations in this study, future investigations 
with a larger sample size would provide more accurate results and possibly show 
a stronger correlation between the levels of expression of NRP2 and the stage 
melanoma. Even &o, NRP2 does show promise as a biomarker for melanoma. 
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